Zensar Technologies recently announced a strong financial performance for Q1 FY26. Consolidated revenues reached ₹1,385 crore, demonstrating a 7.5% year-on-year growth. The company also reported a healthy 15.3% year-on-year increase in Profit After Tax (PAT), reaching ₹182 crore. Growth was notable across several business segments, with Healthcare & Life Sciences (HLS) and Telecom, Media & Technology (TMT) verticals showing significant sequential growth. This was fueled by increasing demand for Generative AI (GenAI) and AI-led automation solutions, as well as next-gen engineering and cloud-based engagements. The company's Cloud Infrastructure & Security & Services segment was a particular highlight with substantial revenue and profit growth. Zensar is actively pursuing strategic partnerships and acquisitions. A notable acquisition was BridgeView Life Sciences in July 2024 for up to $25 million, which aims to bolster Zensar's HLS vertical and expand its expertise in pharma commercial and product launch services. The company also secured a key partner role in the UK Post Office's Digital Capabilities Framework and partnered with Resulticks to expand audience engagement solutions. The company's focus on AI-led transformation is evident, with 20% of new order bookings and 30% of its active order pipeline being influenced by AI. Zensar is also committed to ESG goals, including achieving net-zero carbon emissions by FY45. Attrition rates have reached a record low of 9.8%, indicating strong employee retention.